Income statement
CNY
Annual
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 343M | 305M | 245M | 215M |
| Gross Profit | 48M | 39M | 55M | 53M |
| Operating Income | -26M | -22M | -4M | -80M |
| EBITDA | -24M | -23M | -4M | -59M |
| Net Income | -143M | -145M | -126M | -188M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.072
-17.24% today
Window Change
-98.21%
Window
Oct 8, 2025 → Jun 18, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 174 bars · Oct 8, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
POMDOCTOR Ltd (POM) is a Healthcare stock with a market cap of $280.00M and listed on NASDAQ. The stock last traded around $0.07 and down 98.2% across the available one-year price window (Oct 8, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +12.4%, EPS growth of +1.6%, a dividend yield of 0.0%. What stands out right now is revenue +12.4%, EPS +1.6%, free cash flow +64.8% with operating margin -7.5% and ROIC 44.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Stock Foundry combines POM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
POM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
POM Max Drawdown
-98.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for POM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$215.4M
-12.2% YoY
FY Net Income
-$188.4M
-50.1% YoY
Free Cash Flow
-$15.7M
+28.8% YoY
Revenue Growth
+12.4%
EPS Growth
+1.6%
Gross Margin
13.9%
Net Margin
-41.9%
Income statement
CNY
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 343M | 305M | 245M | 215M |
| Gross Profit | 48M | 39M | 55M | 53M |
| Operating Income | -26M | -22M | -4M | -80M |
| EBITDA | -24M | -23M | -4M | -59M |
| Net Income | -143M | -145M | -126M | -188M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
CNY
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 8M | 7M | 2M | 2M |
| Total Assets | 46M | 66M | 49M | 19M |
| Total Liabilities | 2.1B | 2.0B | 1.9B | 1.8B |
| Shareholder Equity | -2.3B | -2.1B | -2.0B | -1.8B |
| Total Debt | 441M | 413M | 361M | 341M |
| Net Debt | 433M | 407M | 359M | 339M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
16M
+28.8% YoY
Capital Expenditures
0
Free Cash Flow
16M
+28.8% YoY
Key ratios
Gross Margin
13.9%
Operating Margin
-7.5%
Net Margin
-41.9%
ROE
6.5%
Debt / Equity
-0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.